Mariana Chavez Mac Gregor, MD, MSC, on Adjuvant Chemotherapy in Older Patients with Breast Cancer
The breast cancer expert discussed research recently published in Cancer Medicine, which suggested that delays in adjuvant chemotherapy are associated with worse survival in this patient population.
Study findings published in Cancer Medicine indicated that delays in adjuvant chemotherapy are associated with worse survival in older patients with breast cancer.
With everything considered, researchers indicated that providers should avoid delays and begin chemotherapy no later than 90 days after surgery, regardless of the patient’s breast cancer subtype or age.
“This data should encourage providers to take appropriate steps to ensure timely initiation of chemotherapy,” the authors explained.
In an interview with CancerNetwork®, Mariana Chavez Mac Gregor, MD, MSC, a medical oncologist from the MD Anderson Cancer Center, discussed these study findings and how they may shape treatment for this patient population moving forward.
This segment comes from the CancerNetwork® portion of the MJH Life Sciences Medical World News, airing daily on all MJH Life Sciences channels.
Reference:
Smith-Graziani D, Lei X, Giordano SH, Zhao H, Karutui M, Chavez-MacGregor M. Delayed initiation of adjuvant chemotherapy in older women with breast cancer. Cancer Medicine. doi: 10.1002/cam4.3363
Treatment Combinations for HER2-Positive Breast Cancer
March 7th 2013As part of our coverage for the 30th Annual Miami Breast Cancer Conference, we bring you an interview with Dr. Mark Pegram, director of the breast cancer program at the Stanford Women’s Cancer Center and codirector of the molecular therapeutics program. Dr. Pegram will be discussing the potential for novel HER2 combination therapies at the conference.
